Tag: biosimilars

Future Biosimilars: The 2025-2030 Patent Cliff and Market Entry Guide

Explore the upcoming wave of biosimilar market entries as major biologic patents expire between 2025 and 2030. Learn about Keytruda, Eylea, and the cost savings for patients.

Generic Drug Savings: Real Numbers and Healthcare Statistics

Explore the real numbers behind generic drug savings. Learn about the 90/13 paradox, the impact of biosimilars, and how patent thickets affect your healthcare costs.

Immunogenicity in Biosimilars: Why Immune Responses May Differ from Reference Biologics

Biosimilars are not exact copies of biologics-tiny manufacturing differences can trigger immune responses. Learn why some patients develop anti-drug antibodies and how this affects safety and effectiveness.